Second Quarter Revenue Increased 12% to $165
Million
Raising Revenue Guidance $655 to $667
Million and Adjusted EBITDA to $33 to $37 Million
NeoGenomics, Inc. (NASDAQ: NEO) (the
“Company”), a leading oncology testing services
company, today announced its second-quarter results for the period
ended June 30, 2024.
Second Quarter
2024 Highlights As Compared To Second Quarter 2023
- Consolidated revenue increased 12% to
$165 million
- Clinical Services revenue increased 15% to $141
million
- Advanced Diagnostics revenue decreased 3% to $23
million
- Net loss decreased 23% to $19 million
- Adjusted EBITDA increased 630% to positive $11
million
“The second quarter represents the fourth consecutive positive
Adjusted EBITDA quarter with continued strong growth in volumes,
revenues, and earnings,” said Chris Smith, NeoGenomics’ Chief
Executive Officer. “We are well positioned to continue the momentum
in the second half of the year and are committed to expanding our
broad menu to help deliver innovative care for patients and driving
long-term sustainable growth.”
Second-Quarter Results
Consolidated revenue for the second quarter of 2024 was $165
million, an increase of 12% over the same period in 2023. Clinical
Services revenue of $141 million increased year-over-year by 15%.
Clinical test volume(1) increased by 6% year-over-year. Average
revenue per clinical test (“revenue per test”) increased by 9% to
$454. Advanced Diagnostics revenue decreased by 3% to $23 million
compared to the second quarter of 2023.
Consolidated gross profit for the second quarter of 2024 was
$72.5 million, an increase of 21.0% compared to the second quarter
of 2023. This increase was primarily due to an increase in revenue
partially offset by higher compensation and benefit costs.
Consolidated gross profit margin, including amortization of
acquired intangible assets and stock-based compensation expense,
was 44.1%. Adjusted Gross Profit Margin(2), excluding amortization
of acquired intangible assets and stock-based compensation expense,
was 47.3%.
Operating expenses for the second quarter of 2023 were $94
million, an increase of $5 million, or 5%, compared to the second
quarter of 2023. Operating expenses included higher compensation
and benefit costs as well as an increase in legal and professional
fees. These increases were partially offset by a decrease in
restructuring activities.
Net loss for the quarter decreased $6 million, or 23%, to $19
million compared to net loss of $24 million for the second quarter
of 2023.
Adjusted EBITDA(2) increased $13 million, or 630%, to positive
$11 million compared to negative $2 million in the second quarter
of 2023. Adjusted Net Income(2) was $4 million compared to Adjusted
Net Loss(2) of $7 million in the second quarter of 2023.
Cash and cash equivalents and marketable securities totaled $388
million at quarter end.
2024 Financial
Guidance(3)
The Company revised its full-year 2024 guidance(3), as initially
issued on February 20, 2024.
FY 2023
Initial FY 2024
Guidance
Revised FY 2024
Guidance(3)
YOY % Change from FY
2023
(in millions)
Actual
Low
High
Low
High
Low
High
Consolidated revenue
$592
$650
$660
$655
$667
11%
13%
Net loss
$(88)
$(72)
$(66)
$(88)
$(81)
—%
8%
Adjusted EBITDA
$3
$21
$24
$33
$37
1000%
1133%
________________________________________
(1)
Clinical testing excludes tests and
revenue for Advanced Diagnostics.
(2)
The Company has provided adjusted
financial information that has not been prepared in accordance with
GAAP, including Adjusted EBITDA, Adjusted Gross Profit Margin,
Adjusted Net Loss, and Adjusted Diluted EPS. Each of these measures
is defined in the section of this report entitled “Use of Non-GAAP
Financial Measures.” See also the tables reconciling such measures
to their closest GAAP equivalent.
(3)
The Company reserves the right to adjust
this guidance at any time based on the ongoing execution of its
business plan. Current and prospective investors are encouraged to
perform their own due diligence before buying or selling any of the
Company’s securities, and are reminded that the foregoing estimates
should not be construed as a guarantee of future performance.
Conference Call
The Company has scheduled a webcast and conference call to
discuss its second quarter 2024 results on Monday, July 29, 2024 at
4:30 p.m. Eastern Time. To access the live call via telephone,
interested investors should dial (888) 506-0062 (domestic) or (973)
528-0011 (international) at least five minutes prior to the call.
The participant access code provided for this call is 276062. The
live webcast may be accessed by visiting the Investor Relations
section of our website at ir.neogenomics.com. A replay of the
webcast will be available shortly after the conclusion of the call
and will be archived on the company’s website.
About NeoGenomics, Inc.
NeoGenomics, Inc. specializes in cancer genetics testing and
information services, providing one of the most comprehensive
oncology-focused testing menus in the world for physicians to help
them diagnose and treat cancer. The Company’s Advanced Diagnostics
Division serves pharmaceutical clients in clinical trials and drug
development.
NeoGenomics is committed to connecting patients with life
altering therapies and trials. We believe that, together, with our
partners, we can help patients with cancer today and the next
person diagnosed tomorrow. In carrying out these commitments,
NeoGenomics adheres to relevant data protection laws, provides
transparency and choice to patients regarding the handling and use
of their data through our Notice of Privacy Practices, and has
invested in leading technologies to secure the data we
maintain.
Headquartered in Fort Myers, FL, NeoGenomics operates CAP
accredited and CLIA certified laboratories for full-service sample
processing in Fort Myers, Florida; Aliso Viejo and San Diego,
California; Research Triangle Park, North Carolina; and Houston,
Texas; and a CAP accredited full-service, sample-processing
laboratory in Cambridge, United Kingdom. NeoGenomics also has
several, small, non-processing laboratory locations across the
United States for providing analysis services. NeoGenomics serves
the needs of pathologists, oncologists, academic centers, hospital
systems, pharmaceutical firms, integrated service delivery
networks, and managed care organizations throughout the United
States, and a pharmaceutical firm in Europe.
Forward Looking Statements
This press release includes forward-looking statements. These
forward-looking statements generally can be identified by the use
of words such as “anticipate,” “expect,” “plan,” “could,” “would,”
“may,” “will,” “believe,” “estimate,” “forecast,” “goal,”
“project,” “guidance,” “plan,” “potential” and other words of
similar meaning, although not all forward-looking statements
include these words. This press release includes forward-looking
statements. These forward-looking statements address various
matters, including statements regarding improving operational
efficiency, returning to profitable growth and its ongoing
executive recruitment process. Each forward-looking statement
contained in this press release is subject to a number of risks and
uncertainties that could cause actual results to differ materially
from those expressed or implied by such statement. Applicable risks
and uncertainties include, among others, the Company's ability to
identify and implement appropriate financial and operational
initiatives to improve performance, to identify and recruit
executive candidates, to continue gaining new customers, offer new
types of tests, integrate its acquisitions and otherwise implement
its business plan, and the risks identified under the heading "Risk
Factors" contained in the Company's Annual Report on Form 10-K,
Quarterly Reports on Form 10-Q and the Company's other filings with
the Securities and Exchange Commission.
We caution investors not to place undue reliance on the
forward-looking statements contained in this press release. You are
encouraged to read our filings with the SEC, available at
www.sec.gov, for a discussion of these and other risks and
uncertainties. The forward-looking statements in this press release
speak only as of the date of this document (unless another date is
indicated), and we undertake no obligation to update or revise any
of these statements. Our business is subject to substantial risks
and uncertainties, including those referenced above. Investors,
potential investors, and others should give careful consideration
to these risks and uncertainties.
NeoGenomics, Inc.
CONDENSED CONSOLIDATED BALANCE
SHEETS
(in thousands)
June 30, 2024
(unaudited)
December 31, 2023
ASSETS
Current assets
Cash and cash equivalents
$
355,085
$
342,488
Marketable securities, at fair value
32,770
72,715
Accounts receivable, net
146,581
131,227
Inventories
23,214
24,156
Prepaid assets
17,396
17,987
Other current assets
9,157
8,239
Total current assets
584,203
596,812
Property and equipment, net
92,158
92,012
Operating lease right-of-use assets
83,671
91,769
Intangible assets, net
356,404
373,128
Goodwill
522,766
522,766
Other assets
4,075
4,742
Total non-current assets
1,059,074
1,084,417
Total assets
$
1,643,277
$
1,681,229
LIABILITIES AND STOCKHOLDERS’
EQUITY
Current liabilities
Accounts payable and other current
liabilities
$
86,312
$
90,694
Current portion of operating lease
liabilities
3,574
5,610
Current portion of convertible senior
notes, net
200,073
—
Total current liabilities
289,959
96,304
Long-term liabilities
Operating lease liabilities
63,294
67,871
Convertible senior notes, net
339,577
538,198
Deferred income tax liabilities, net
23,015
24,285
Other long-term liabilities
11,548
13,034
Total long-term liabilities
437,434
643,388
Total liabilities
$
727,393
$
739,692
Stockholders’ equity
Total stockholders’ equity
$
915,884
$
941,537
Total liabilities and stockholders’
equity
$
1,643,277
$
1,681,229
NeoGenomics, Inc.
CONDENSED CONSOLIDATED
STATEMENTS OF OPERATIONS
(in thousands, except per
share amounts)
(unaudited)
Three Months Ended June
30,
Six Months Ended June
30,
2024
2023
2024
2023
NET REVENUE
Clinical Services
$
141,388
$
123,156
$
275,923
$
238,025
Advanced Diagnostics
23,114
23,761
44,819
46,112
Total net revenue
164,502
146,917
320,742
284,137
COST OF REVENUE
92,008
87,026
182,779
169,432
GROSS PROFIT
72,494
59,891
137,963
114,705
Operating expenses:
General and administrative
63,328
60,308
129,125
121,857
Research and development
7,886
7,502
15,506
14,897
Sales and marketing
21,677
18,901
41,898
35,160
Restructuring charges
1,544
3,074
3,942
7,758
Total operating expenses
94,435
89,785
190,471
179,672
LOSS FROM OPERATIONS
(21,941
)
(29,894
)
(52,508
)
(64,967
)
Interest income
(4,592
)
(4,308
)
(9,426
)
(7,532
)
Interest expense
1,666
1,784
3,351
3,541
Other expense (income), net
2
(730
)
265
(616
)
Loss before taxes
(19,017
)
(26,640
)
(46,698
)
(60,360
)
Income tax benefit
(375
)
(2,309
)
(995
)
(5,234
)
NET LOSS
$
(18,642
)
$
(24,331
)
$
(45,703
)
$
(55,126
)
NET LOSS PER SHARE
Basic
$
(0.15
)
$
(0.19
)
$
(0.36
)
$
(0.44
)
Diluted
$
(0.15
)
$
(0.19
)
$
(0.36
)
$
(0.44
)
WEIGHTED AVERAGE COMMON SHARES
OUTSTANDING
Basic
126,405
125,356
126,257
125,192
Diluted
126,405
125,356
126,257
125,192
NeoGenomics, Inc.
CONDENSED CONSOLIDATED
STATEMENTS OF CASH FLOWS
(in thousands)
(unaudited)
Six Months Ended June
30,
2024
2023
CASH FLOWS FROM OPERATING
ACTIVITIES
Net loss
$
(45,703
)
$
(55,126
)
Adjustments to reconcile net loss to net
cash used in operating activities:
Depreciation
19,651
18,523
Amortization of intangibles
16,723
17,566
Stock-based compensation
16,615
10,463
Non-cash operating lease expense
4,793
4,648
Amortization of convertible debt discount
and debt issue costs
1,452
1,433
Impairment of assets
333
1,660
Other adjustments
159
5
Changes in assets and liabilities, net
(26,046
)
(13,412
)
Net cash used in operating activities
(12,023
)
(14,240
)
CASH FLOWS FROM INVESTING
ACTIVITIES
Purchases of marketable securities
—
(6,756
)
Proceeds from maturities of marketable
securities
40,501
62,868
Purchases of property and equipment
(18,663
)
(17,421
)
Net cash provided by investing
activities
21,838
38,691
CASH FLOWS FROM FINANCING
ACTIVITIES
Repayment of equipment financing
obligations
—
(61
)
Issuance of common stock, net
2,782
1,504
Net cash provided by financing
activities
2,782
1,443
Net change in cash and cash
equivalents
12,597
25,894
Cash and cash equivalents, beginning of
period
342,488
263,180
Cash and cash equivalents, end of
period
$
355,085
$
289,074
Use of Non-GAAP Financial Measures
In order to provide greater transparency regarding our operating
performance, the financial results and financial guidance in this
press release refer to certain non-GAAP financial measures that
involve adjustments to GAAP results. Non-GAAP financial measures
exclude certain income and/or expense items that management
believes are not directly attributable to the Company’s core
operating results and/or certain items that are inconsistent in
amounts and frequency, making it difficult to perform a meaningful
evaluation of our current or past operating performance. Management
believes that the presentation of operating results using non-GAAP
financial measures provides useful supplemental information to
investors by facilitating the analysis of the Company’s core
test-level operating results across reporting periods and when
comparing those same results to those published by our peers. These
non-GAAP financial measures may also assist investors in evaluating
future prospects. Management also uses non-GAAP financial measures
for financial and operational decision making, planning and
forecasting purposes and to manage the business. These non-GAAP
financial measures do not replace the presentation of financial
information in accordance with U.S. GAAP financial results, should
not be considered measures of liquidity, and are unlikely to be
comparable to non-GAAP financial measures provided by other
companies.
Definitions of Non-GAAP Measures
Non-GAAP Adjusted EBITDA
“Adjusted EBITDA” is defined by NeoGenomics as net (loss) income
from continuing operations before: (i) interest income, (ii)
interest expense, (iii) tax (benefit) or expense, (iv) depreciation
and amortization expense, (v) stock-based compensation expense,
and, if applicable in a reporting period, (vi) restructuring
charges, (vii) intellectual property (“IP”) litigation, and (viii)
other significant or non-operating (income) or expenses, net.
Non-GAAP Adjusted Cost of Revenue,
Adjusted Gross Profit and Adjusted Gross Profit Margin
“Adjusted cost of revenue” is defined by NeoGenomics as cost of
revenue before: (i) amortization of acquired intangible assets,
and, if applicable in a reporting period, (ii) stock-based
compensation expense.
“Adjusted gross profit” is defined by NeoGenomics as total
revenue less adjusted cost of revenue.
“Adjusted gross profit margin” is defined by NeoGenomics as
adjusted cost of revenue divided by total revenue.
Non-GAAP Adjusted Net (Loss)
Income
“Adjusted net (loss) income” is defined by NeoGenomics as net
(loss) income from continuing operations plus: (i) amortization of
intangible assets, (ii) stock-based compensation expense, and, if
applicable in a reporting period, (iii) restructuring charges, (iv)
IP litigation, and (v) other significant or non-operating (income)
or expenses, net. If GAAP net (loss) income is negative and
adjusted net (loss) income is positive, adjusted net (loss) income
will also be adjusted to reverse any recognized interest expense
(including any amortization of discounts) on the convertible notes
using the if-converted method unless the effect of this adjustment
on both the adjusted net (loss) income and weighted average diluted
common shares outstanding would be anti-dilutive. If GAAP net
(loss) income is positive and adjusted net (loss) income is
negative, adjusted net (loss) income will also be adjusted to
reverse any recognized interest expense (including any amortization
of discounts) on the convertible notes using the if-converted
method.
Non-GAAP Adjusted Diluted EPS
“Adjusted diluted EPS” is defined by NeoGenomics as adjusted net
(loss) income divided by adjusted diluted shares outstanding. If
GAAP net (loss) income is negative and adjusted net (loss) income
is positive, adjusted diluted shares outstanding will also include
any options or restricted stock that would be outstanding as
dilutive instruments using the treasury stock method and the
weighted average number of common shares that would be outstanding
if the convertible notes were converted into common stock on the
original issue date based on the number of days such common shares
would have been outstanding in the reporting period, until the
effect of these adjustments are anti-dilutive. If GAAP net (loss)
income is positive and adjusted net (loss) income is negative,
adjusted diluted shares outstanding will exclude any options or
restricted stock that would be outstanding as dilutive instruments
using the treasury stock method and the weighted average number of
common shares that would be outstanding if the convertible notes
were converted into common stock on the original issue date based
on the number of days such common shares would have been
outstanding in the reporting period.
Reconciliation of GAAP Net
Loss to Non-GAAP EBITDA and Adjusted EBITDA
(in thousands)
(unaudited)
Three Months Ended June
30,
Six Months Ended June
30,
2024
2023
2024
2023
Net loss (GAAP)
$
(18,642
)
$
(24,331
)
$
(45,703
)
$
(55,126
)
Adjustments to net loss:
Interest income
(4,592
)
(4,308
)
(9,426
)
(7,532
)
Interest expense
1,666
1,784
3,351
3,541
Income tax benefit
(375
)
(2,309
)
(995
)
(5,234
)
Depreciation
9,746
9,475
19,651
18,523
Amortization of intangibles
8,361
8,783
16,723
17,566
EBITDA (non-GAAP)
$
(3,836
)
$
(10,906
)
$
(16,399
)
$
(28,262
)
Further adjustments to EBITDA:
Stock-based compensation expense
8,841
5,705
16,615
10,463
Restructuring charges
1,544
3,074
3,942
7,758
IP litigation
1,962
—
6,243
—
Other significant (income) expenses,
net(4)
2,358
76
3,960
874
Adjusted EBITDA (non-GAAP)
$
10,869
$
(2,051
)
$
14,361
$
(9,167
)
_________________
(4)
For the three months ended June 30, 2024,
other significant (income) expenses, net, includes site closure
costs, severance costs, and fees related to non-recurring legal
matters. For the three months ended June 30, 2023, other
significant (income) expenses, net, includes fees related to a
regulatory matter and other non-recurring items. For the six months
ended June 30, 2024, other significant (income) expenses, net,
includes site closure costs, severance costs, and fees related to
non-recurring legal matters. For the six months ended June 30,
2023, other significant (income) expenses, net, CEO transition
costs, fees related to a regulatory matter and other non-recurring
items.
Reconciliation of Segment and
Consolidated GAAP Cost of Revenue, Gross Profit and Gross Profit
Margin to
Non-GAAP Adjusted Cost of
Revenue, Adjusted Gross Profit and Adjusted Gross Profit
Margin
(dollars in thousands)
(unaudited)
Three Months Ended June
30,
Six Months Ended June
30,
2024
2023
% Change
2024
2023
% Change
Clinical Services:
Total revenue (GAAP)
$
141,388
$
123,156
14.8
%
$
275,923
$
238,025
15.9
%
Cost of revenue (GAAP)
$
78,094
$
71,746
8.8
%
$
154,938
$
139,038
11.4
%
Adjustments to cost of revenue(5)
(4,552
)
(4,263
)
(9,159
)
(8,527
)
Adjusted cost of revenue
(non-GAAP)
$
73,542
$
67,483
9.0
%
$
145,779
$
130,511
11.7
%
Gross profit (GAAP)
$
63,294
$
51,410
23.1
%
$
120,985
$
98,987
22.2
%
Adjusted gross profit (non-GAAP
)
$
67,846
$
55,673
21.9
%
$
130,144
$
107,514
21.0
%
Gross profit margin (GAAP)
44.8
%
41.7
%
43.8
%
41.6
%
Adjusted gross profit margin
(non-GAAP)
48.0
%
45.2
%
47.2
%
45.2
%
Advanced Diagnostics:
Total revenue (GAAP)
$
23,114
$
23,761
(2.7
)%
$
44,819
$
46,112
(2.8
)%
Cost of revenue (GAAP)
$
13,914
$
15,280
(8.9
)%
$
27,841
$
30,394
(8.4
)%
Adjustments to cost of revenue(6)
(715
)
(590
)
(1,413
)
(1,179
)
Adjusted cost of revenue
(non-GAAP)
$
13,199
$
14,690
(10.1
)%
$
26,428
$
29,215
(9.5
)%
Gross profit (GAAP)
$
9,200
$
8,481
8.5
%
$
16,978
$
15,718
8.0
%
Adjusted gross profit (non-GAAP
)
$
9,915
$
9,071
9.3
%
$
18,391
$
16,897
8.8
%
Gross profit margin (GAAP)
39.8
%
35.7
%
37.9
%
34.1
%
Adjusted gross profit margin
(non-GAAP)
42.9
%
38.2
%
41.0
%
36.6
%
Consolidated:
Total revenue (GAAP)
$
164,502
$
146,917
12.0
%
$
320,742
$
284,137
12.9
%
Cost of revenue (GAAP)
$
92,008
$
87,026
5.7
%
$
182,779
$
169,432
7.9
%
Adjustments to cost of revenue(5)(6)
(5,267
)
(4,853
)
(10,572
)
(9,706
)
Adjusted cost of revenue
(non-GAAP)
$
86,741
$
82,173
5.6
%
$
172,207
$
159,726
7.8
%
Gross profit (GAAP)
$
72,494
$
59,891
21.0
%
$
137,963
$
114,705
20.3
%
Adjusted gross profit (non-GAAP
)
$
77,761
$
64,744
20.1
%
$
148,535
$
124,411
19.4
%
Gross profit margin (GAAP)
44.1
%
40.8
%
43.0
%
40.4
%
Adjusted gross profit margin
(non-GAAP)
47.3
%
44.1
%
46.3
%
43.8
%
_______________
(5)
Clinical Services cost of revenue
adjustments for the three months ended June 30, 2024 includes $4.3
million of amortization of acquired intangible assets and $0.2
million of stock-based compensation. Clinical Services cost of
revenue adjustments for the three months ended June 30, 2023
includes $4.3 million of amortization of acquired intangible
assets. Clinical Services cost of revenue adjustments for the six
months ended June 30, 2024 includes $8.6 million of amortization of
acquired intangible assets and $0.5 million of stock-based
compensation. Clinical Services cost of revenue adjustments for the
six months ended June 30, 2023 includes $8.5 million of
amortization of acquired intangible assets. There were no
stock-based compensation amounts recorded for the three and six
months ended June 30, 2023.
(6)
Advanced Diagnostics cost of revenue
adjustments for the three months ended June 30, 2024 includes $0.6
million of amortization of acquired intangible assets and $0.1
million of stock-based compensation. Advanced Diagnostics cost of
revenue adjustments for the three months ended June 30, 2023
includes $0.6 million of amortization of acquired intangible
assets. Advanced Diagnostics cost of revenue adjustments for the
six months ended June 30, 2024 includes $1.2 million of
amortization of acquired intangible assets and $0.2 million of
stock-based compensation. Advanced Diagnostics cost of revenue
adjustments for the six months ended June 30, 2023 includes $1.2
million of amortization of acquired intangible assets. There were
no stock-based compensation amounts recorded for the three and six
months ended June 30, 2023.
Reconciliation of GAAP Net
Loss to Non-GAAP Adjusted Net Loss
and GAAP EPS to Non-GAAP
Adjusted EPS
(in thousands, except per
share amounts)
(unaudited)
Three Months Ended June
30,
Six Months Ended June
30,
2024
2023
2024
2023
Net loss (GAAP)
$
(18,642
)
$
(24,331
)
$
(45,703
)
$
(55,126
)
Adjustments to net loss, net of tax:
Amortization of intangibles
8,361
8,783
16,723
17,566
Stock-based compensation expense
8,841
5,705
16,615
10,463
Restructuring charges
1,544
3,074
3,942
7,758
IP litigation
1,962
—
6,243
—
Other significant (income) expenses,
net(7)
2,358
76
3,960
874
Adjusted net loss (non-GAAP)
$
4,424
$
(6,693
)
$
1,780
$
(18,465
)
Net loss per common share
(GAAP)
Diluted EPS
$
(0.15
)
$
(0.19
)
$
(0.36
)
$
(0.44
)
Adjustments to diluted loss income per
share:
Amortization of intangibles
0.07
0.07
0.13
0.14
Stock-based compensation expense
0.07
0.05
0.13
0.08
Restructuring charges
0.01
0.02
0.03
0.06
IP litigation
0.02
—
0.05
—
Other significant (income) expenses,
net(7)
0.02
—
0.03
0.01
Rounding and impact of diluted shares in
adjusted diluted shares(8)
(0.01
)
—
—
—
Adjusted diluted EPS (non-GAAP)
$
0.03
$
(0.05
)
$
0.01
$
(0.15
)
Weighted average shares used in
computation of adjusted diluted EPS:
Diluted common shares (GAAP)
126,405
125,356
126,257
125,192
Dilutive effect of options, restricted
stock, and converted shares(9)(10)
—
—
—
—
Adjusted diluted shares outstanding
(non-GAAP)
126,405
125,356
126,257
125,192
_________________
(7)
For the three months ended June 30, 2024,
other significant (income) expenses, net, includes site closure
costs, severance costs, and fees related to non-recurring legal
matters. For the three months ended June 30, 2023, other
significant (income) expenses, net, includes fees related to a
regulatory matter and other non-recurring items. For the six months
ended June 30, 2024, other significant (income) expenses, net,
includes site closure costs, severance costs, and fees related to
non-recurring legal matters. For the six months ended June 30,
2023, other significant (income) expenses, net, includes CEO
transition costs, fees related to a regulatory matter and other
non-recurring items.
(8)
This adjustment is for rounding and, in
those periods in which GAAP net (loss) income is negative and
adjusted net (loss) income is positive or GAAP net (loss) income is
positive and adjusted net (loss) income is negative, also
compensates for the effects of additional diluted shares included
or excluded in adjusted diluted shares outstanding for the treasury
stock impact of outstanding stock options and restricted stock and
the if-converted impact of convertible notes.
(9)
In those periods in which GAAP net (loss)
income is negative and adjusted net (loss) income is positive, this
adjustment includes any options or restricted stock that would be
outstanding as dilutive instruments using the treasury stock method
and the weighted average number of common shares that would be
outstanding if the convertible notes were converted into common
stock on the original issue date based on the number of days such
common shares would have been outstanding in the reporting period,
until the effect of these adjustments are anti-dilutive.
(10)
In those periods in which GAAP net (loss)
income is positive and adjusted net (loss) income is negative, this
adjustment excludes any options or restricted stock that would be
outstanding as dilutive instruments using the treasury stock method
and the weighted average number of common shares that would be
outstanding if the convertible notes were converted into common
stock on the original issue date based on the number of days such
common shares would have been outstanding in the reporting
period.
Reconciliation of Non-GAAP
Financial Guidance to Corresponding GAAP Measures
(in thousands, except per
share amounts)
(unaudited)
GAAP net loss in 2024 will be impacted by
certain charges, including: (i) expense related to the amortization
of intangible assets, (ii) stock-based compensation, (iii)
restructuring charges, and (iv) other one-time expenses. These
charges have been included in GAAP net loss available to
stockholders and GAAP net loss per share; however, they have been
removed from adjusted net loss and adjusted diluted net loss per
share.
The following table reconciles the
Company’s 2024 outlook for net loss and EPS to the corresponding
non-GAAP measures of adjusted net loss, adjusted EBITDA, and
adjusted diluted EPS:
Year Ended December 31,
2024
Low Range
High Range
Net loss (GAAP)
$
(88,000
)
$
(81,000
)
Amortization of intangibles
33,000
33,000
Stock-based compensation expenses
33,000
32,000
Restructuring charges
5,000
5,000
Other one-time expenses
20,000
20,000
Adjusted net loss (non-GAAP)
3,000
9,000
Interest and taxes
(11,000
)
(11,000
)
Depreciation
41,000
39,000
Adjusted EBITDA (non-GAAP)
$
33,000
$
37,000
Net loss per diluted share
(GAAP)
$
(0.69
)
$
(0.64
)
Adjustments to net loss per diluted
share:
Amortization of intangibles
0.26
0.26
Stock-based compensation expenses
0.26
0.25
Restructuring charges
0.04
0.04
Other one-time expenses
0.16
0.16
Rounding and impact of diluted shares in
adjusted diluted shares(11)
(0.01
)
—
Adjusted diluted EPS(12)
(non-GAAP)
$
0.02
$
0.07
Weighted average assumed shares
outstanding in 2024:
Diluted shares (GAAP)
127,000
127,000
Options, restricted stock, and converted
shares not included in diluted shares(12)
—
—
Adjusted diluted shares outstanding
(non-GAAP)
127,000
127,000
_________________
(11)
This adjustment is for rounding and, in
those periods in which GAAP net (loss) income is negative and
adjusted net (loss) income is positive, also compensates for the
effects of additional diluted shares included in adjusted diluted
shares outstanding for the treasury stock impact of outstanding
stock options and restricted stock and the if-converted impact of
convertible notes.
(12)
For those periods in which GAAP net (loss)
income is negative and adjusted net (loss) income is positive, this
adjustment includes any options or restricted stock that would be
outstanding as dilutive instruments using the treasury stock method
and the weighted average number of shares that would be outstanding
if the convertible notes were converted into common stock on the
original issue date based on the number of days such shares would
have been outstanding in the reporting period, until the effect of
these adjustments are anti-dilutive.
Supplemental
Information
Clinical(13) Tests Performed
and Revenue
(unaudited)
Three Months Ended June
30,
Six Months Ended June
30,
2024
2023
% Change
2024
2023
% Change
Clinical(13):
Number of tests performed
311,670
295,116
5.6
%
612,497
580,592
5.5
%
Average revenue/test
$
454
$
417
8.9
%
$
450
$
410
9.8
%
_________________
(13)
Excludes tests and revenue for Advanced
Diagnostics.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240729440384/en/
NeoGenomics, Inc. Kendra Sweeney Vice President, Investor
Relations and ESG Kendra.sweeney@neogenomics.com T:
+1-239-877-7474
NeoGenomics (NASDAQ:NEO)
過去 株価チャート
から 6 2024 まで 7 2024
NeoGenomics (NASDAQ:NEO)
過去 株価チャート
から 7 2023 まで 7 2024